参考文献/References:
[1] Saeedi P,Petersohn I,Salpea P,et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045:results from the International Diabetes Federation Diabetes Atlas,9th edition[J]. Diabetes Res Clin Pract,2019,157:107843.
[2] 2018中国国际心力衰竭大会（CIHFC）—暨中国医师协会心力衰竭专业委员会年会在北京隆重召开[J]. 健康之家,2018(4):94-95.
[3] Authors/Task Force Members,Rydén L,Grant PJ,et al. ESC Guidelines on diabetes,pre-diabetes,and cardiovascular diseases developed in collaboration with the EASD:the Task Force on diabetes,pre-diabetes,and cardiovascular diseases of the European Society of Cardiology(ESC) and developed in collaboration with the European Association for the Study of Diabetes(EASD).?Eur Heart J,2013,34(39):3035-3087.
[4] Seferovi? PM,Paulus WJ,Rosano G,et al. Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases[J]. Eur J Heart Fail,2024,26(9):1893-1903.
[5] Quaiyoom A,Kumar R. An overview of diabetic cardiomyopathy[J]. Curr Diabetes Rev,2024,20(5):e121023222139.
[6] 中华医学会心血管病学分会,中国医师协会心血管内科医师分会,中国医师协会心力衰竭专业委员会,等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志,2024,52(3):235-275.
[7] Tuleta I,Frangogiannis NG. Fibrosis of the diabetic heart:clinical significance,molecular mechanisms,and therapeutic opportunities[J]. Adv Drug Deliv Rev,2021,176:113904.
[8] Zhi F,Pu X,Wei W,et al. Modulating mitochondrial dynamics ameliorates left ventricular dysfunction by suppressing diverse cell death pathways after diabetic cardiomyopathy[J]. Int J Med Sci,2024,21(12):2324-2333.
[9] Marx N,Federici M,Schütt K,et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes[J]. Eur Heart J,2023,44(39):4043-4140.
[10] Horie T,Ono K,Nishi H,et al. MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes[J]. Biochem Biophys Res Commun,2009,389(2):315-320.
[11] Bernardo BC,Ooi JY,Matsumoto A,et al. Sex differences in response to miRNA-34a therapy in mouse models of cardiac disease:identification of sex-,disease- and treatment-regulated miRNAs[J]. J Physiol,2016,594(20):5959-5974.
[12] Qi Y,Wu H,Mai C,et al. LncRNA-MIAT-mediated miR-214-3p silencing is responsible for IL-17 production and cardiac fibrosis in diabetic cardiomyopathy[J]. Front Cell Dev Biol,2020,8:243.
[13] Taqueti VR,Di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options:JACC state-of-the-art review[J]. J Am Coll Cardiol,2018,72(21):2625-2641.
[14] Cojan-Minzat BO,Zlibut A,Agoston-Coldea L. Non-ischemic dilated cardiomyopathy and cardiac fibrosis[J]. Heart Fail Rev,2021,26(5):1081-1101.
[15] Authors/Task Force Members:;McDonagh TA,Metra M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). With the special contribution of the Heart Failure Association(HFA) of the ESC[J]. ?Eur J Heart Fail,2022,24(1):4-131.
[16] Yoshino Y,Kumon H,Mori T,et al. Effects of AGXT2 variants on blood pressure and blood sugar among 750 older Japanese subjects recruited by the complete enumeration survey method[J]. BMC Genomics,2021,22(1):287.
[17] Hao M,Huang X,Liu X,et al. Novel model predicts diastolic cardiac dysfunction in type 2 diabetes[J]. Ann Med,2023,55(1):766-777.
[18] Liu J,Zhang Y,Tian Y,et al. Integrative biology of extracellular vesicles in diabetes mellitus and diabetic complications[J]. Theranostics,2022,12(3):1342-1372.
[19] 国家老年医学中心,中华医学会老年医学分会,中国老年保健协会糖尿病专业委员会. 中国老年糖尿病诊疗指南（2024版）[J]. 中华糖尿病杂志,2024,16(2):147-189.
[20] Wang Y,Zhou Y,Zhang Y,et al. Female is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes[J]. Diabetes Metab Syndr Obes,2023,16:2355-2364.
[21] ?lvarez-Zaballos S,Martínez-Sellés M. Impact of sex and diabetes in patients with heart failure[J]. Curr Heart Fail Rep,2024,21(4):389-395.
[22] Toedebusch R,Belenchia A,Pulakat L. Diabetic cardiomyopathy:impact of biological sex on disease development and molecular signatures[J]. Front Physiol,2018,9:453.
[23] Singh AK,Singh R. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes:a systematic review and meta-analysis of cardio-vascular outcome trials[J]. Diabetes Metab Syndr,2020,14(3):181-187.
[24] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2020年版）[J]. 中华糖尿病杂志,2021,13(4):315-409.
[25] Neeland IJ,Ross R,Després JP,et al. Visceral and ectopic fat,atherosclerosis,and cardiometabolic disease:a position statement[J]. Lancet Diabetes Endocrinol,2019,7(9):715-725.
[26] Jiang L,Shi K,Guo YK,et al. The additive effects of obesity on myocardial microcirculation in diabetic individuals:a cardiac magnetic resonance first-pass perfusion study[J]. Cardiovasc Diabetol,2020,19(1):52.
[27] Levelt E,Mahmod M,Piechnik SK,et al. Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes[J]. Diabetes,2016,65(1):44-52.
[28] Li W,Katzmarzyk PT,Horswell R,et al. Body mass index and heart failure among patients with type 2 diabetes mellitus[J].?Circ Heart Fail,2015,8(3):455-463.
[29] van de Weijer T,Schrauwen-Hinderling VB,Schrauwen P. Lipotoxicity in type 2 diabetic cardiomyopathy[J]. Cardiovasc Res,2011,92(1):10-18.
[30] Writing Committee;Douglas PS,Mack MJ,et al. 2022 ACC Health Policy Statement on Building Respect,Civility,and Inclusion in the Cardiovascular Workplace:A Report of the American College of Cardiology Solution Set Oversight Committee[J]. J Am Coll Cardiol,2022,79(21):2153-2184.
[31] Julián MT,Pérez-Montes de Oca A,Julve J,et al. The double burden:type 1 diabetes and heart failure-a comprehensive review[J]. Cardiovasc Diabetol,2024,23(1):65.
[32] McAllister DA,Read SH,Kerssens J,et al. Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus[J]. Circulation,2018,138(24):2774-2786.
[33] Rawshani A,Rawshani A,Franzén S,et al. Range of risk factor levels:control,mortality,and cardiovascular outcomes in type 1 diabetes mellitus[J]. Circulation,2017,135(16):1522-1531.
[34] Fang ZY,Prins JB,Marwick TH. Diabetic cardiomyopathy:evidence,mechanisms,and therapeutic implications[J].?Endocr Rev,2004,25(4):543-567.
[35] Mathieu C,Dandona P,Gillard P,et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes(the DEPICT-2 Study):24-week results from a randomized controlled trial[J]. Diabetes care,2018,41(9):1938-1946.
[36] Rawshani A,Sattar N,Franzén S,et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset:a nationwide,register-based cohort study[J]. Lancet,2018,392(10146):477-486.
[37] Hoek AG,Dal Canto E,Wenker E,et al. Epidemiology of heart failure in diabetes:a disease in disguise[J]. Diabetologia ,2024,67(4):574-601.
[38] Li Z,Shi Y,Xia Y,et al. Disparate clinical characteristics and prognosis of HFpEF versus HFrEF phenotype of diabetic cardiomyopathy[J]. J Clin Med,2023,12(4):1565.
[39] Khan LA,Khan MS,Ambrosy AP,et al. Selective aldose reductase inhibition as a treatment for diabetic cardiomyopathy:summary of the ARISE-HF trial[J]. Heart Fail Rev,2024,29(5):1157-1160.
[40] Chen Z,Li S,Liu M,et al. Nicorandil alleviates cardiac microvascular ferroptosis in diabetic cardiomyopathy:role of the mitochondria-localized AMPK-Parkin-ACSL4 signaling pathway[J]. Pharmacol Res,2024,200:107057.
[41] Zhu N,Zhu L,Huang B,et al. Galectin-3 inhibition ameliorates streptozotocin-induced diabetic cardiomyopathy in mice[J]. Front Cardiovasc Med,2022,9:868372.
[42] Hershberger RE,Givertz MM,Ho CY,et al. Genetic evaluation of cardiomyopathy:a clinical practice resource of the American College of Medical Genetics and Genomics(ACMG)[J]. Genet Med,2018,20(9):899-909.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(10):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(10):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(10):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(10):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(10):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]王静娜,侯瑞田,史亦男,等.糖尿病心肌病发病机制及病理改变研究进展[J].心血管病学进展,2016,(4):412.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.022]
WANG Jingna,HOU Ruitian,SHI Yinan,et al.Research Progress on Pathogenesis and Pathological Changes
of Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(10):412.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.022]
[7]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(10):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[8]杨沫,姜文锡.线粒体功能异常在糖尿病心肌病发病机制中的作用[J].心血管病学进展,2015,(6):731.[doi:10.3969/j.issn.1004-3934.2015.06.019]
YANG Mo,JIANG Wenxi.Mitochondrial Dysfunction of Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2015,(10):731.[doi:10.3969/j.issn.1004-3934.2015.06.019]
[9]朱月红,戴启明.糖尿病心肌病的内质网病变机制及干预[J].心血管病学进展,2015,(6):738.[doi:10.3969/j.issn.1004-3934.2015.06.021]
ZHU Yuehong,DAI Qiming.Advance of Mechanism and Intervention of Endoplasmic Reticulum in
Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2015,(10):738.[doi:10.3969/j.issn.1004-3934.2015.06.021]
[10]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(10):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[11]周媛媛 梁羽.蛋白质O-GlcNAc修饰在心血管疾病的损伤作用[J].心血管病学进展,2025,(3):235.[doi:10.16806/j.cnki.issn.1004-3934.2025.03.010]
ZHOU Yuanyuan,LIANG Yu.Harmful Effect of Protein O-GlcNAc Modification in Cardiovascular System[J].Advances in Cardiovascular Diseases,2025,(10):235.[doi:10.16806/j.cnki.issn.1004-3934.2025.03.010]